Goldline Pharmaceutical Limited

This section provides an overview of the Indian macro-economy, highlighting its resilience and stability despite geopolitical challenges. It discusses various economic indicators, including growth rates, inflation, and foreign direct investment flows. The text also touches upon the performance of different sectors, noting trends in Gross Fixed Capital Formation (GFCF) and the performance of the manufacturing and services sectors.

The provided text covers various aspects of the Indian economy, including consumption trends, financial sector performance, inflation dynamics, and macroeconomic stability. It details the recovery of the economy post-pandemic, the government's efforts to manage fiscal consolidation, and the performance of the monetary policy by the RBI. Furthermore, it discusses the structure of the pharmaceutical industry, highlighting India's leadership in vaccine supply and generic medicines.

The pharmaceutical and biotechnology industry is characterized by various market dynamics, including the growth of contract research and manufacturing services (CRAMS) and the expansion of the biosimilars market. The global medicine market is projected to grow, with different regional markets showing varied growth trajectories influenced by factors like patent expirations and payer actions. The Indian pharmaceutical industry is a significant global player, ranking high in production volume and API manufacturing, and is expected to see substantial growth in the coming years. Furthermore, the industry has shown resilience in innovation, particularly in vaccine technology, and is working on policy frameworks to support research and development.

The pharmaceutical sector in India is receiving significant government support and has shown healthy growth, with various initiatives aimed at boosting research and development. The government has introduced several programs, such as promoting research and innovation through Centres of Excellence and earmarking funds for bulk drug parks and medical device parks. The sector is a key part of India's foreign trade, with substantial exports, and foreign investment is being encouraged under certain guidelines. Market size projections indicate substantial future growth, and various drivers like rising demand, policy support, and the rise of digital health technologies are shaping the industry's trajectory. However, the industry faces challenges related to workforce skills, supply chain disruptions, regulatory compliance, and high R&D costs.

The company is engaged in marketing pharmaceutical products under the brand name "Goldline," utilizing a third-party manufacturing model where contractual arrangements are established to ensure product quality and regulatory compliance. The products are segmented into five distinct lines: Goldline Pharma, Goldline Cardinal, Goldline Aayushman, Goldline InLife, and Goldline Wellness. The company markets these products exclusively under the Goldline brand, with distributors forming the main channel to end-users. The company also provides material supply and procurement support to hospitals and healthcare partners through its promoter group entities.

This section details a diverse portfolio of pharmaceutical products, including various brand names and their compositions, which span across different therapeutic areas. The products include oral antibiotics, neuro vitamins, dietary supplements for various conditions like osteoarthritis, anti-hypertensives, and treatments for gastrointestinal disorders. Specific formulations are listed with their active ingredients and indications for use.

This section details various pharmaceutical products offered by the issuer, including antibiotics, anti-allergic agents, supplements, and anti-diabetic medications. The products listed include various forms of CefuroximeAxetil, Montelukast, various vitamins, anti-hypertensive combinations, and different combinations of Glimepiride and Metformin for diabetes management. There are also products for anti-diabetic treatments involving Atorvastatin and Fenofibrate, as well as various formulations for Vitamin D deficiency and anti-platelet therapy.

This section details a variety of pharmaceutical products offered by the issuer, primarily focusing on treatments for various medical conditions. The products include formulations for anxiety management, anti-hypertensive therapy, neuropathic pain, and oral anti-diabetic treatments. Specific drug combinations mentioned involve Clonazepam, Escitalopram, Olmesartan Medoxomil, various combinations of Telmisartan and HCTZ, Metoprolol, Amlodipine, Pregabalin, Nortriptyline, Rosuvastatin, Febuxostat, Teneligliptin, Metformin, and Sitagliptin.

This section details various pharmaceutical products offered by the issuer, including anti-diabetic, anti-platelet, anti-allergic, and antibiotic formulations. The products listed cover treatments for conditions such as diabetes, dyslipidemia, hypothyroidism, nausea and vomiting in pregnancy, coughs, and various infections. The portfolio also includes dietary supplements and pediatric formulations.

This section details a variety of pharmaceutical and dietary products offered by the issuer, including various antibiotics, vitamins, minerals, and supplements. The listed products include injectable antibiotics such as Piperacillin/Tazobactam, Meropenem, and Cefepime, alongside various vitamin and mineral supplements, anti-oxidants, and anti-septic liquids for gargles.

The company's business process involves several key stages, starting with market research to identify high-demand pharmaceutical products and therapeutic segments. This is followed by contract manufacturing management, where they partner with third-party manufacturers to produce products, ensuring adherence to quality standards and production timelines. Other core functions include branding and packaging design, logistics and supply chain management, distributor and customer relationship management, sales and marketing, compliance, financial management, performance monitoring, and business growth strategies. Competitive strengths include an asset-light business model, strong supplier relationships, and a well-developed distribution network.

The company details its workforce, noting that all employees are permanent and the company does not employ contract labor. As of December 31, 2025, the company employed approximately 112 individuals, with specific details regarding EPF and ESIC deposits for the period. The business is not considered a manufacturing concern, and the operations are not dependent on seasonal or weather conditions. The company complies with environmental laws in India and ensures adherence to health and safety regulations. The company relies on third-party manufacturing partners for its products and maintains quality control through designated officers. Furthermore, the company has registered numerous trademarks under the Trademarks Act, 1999.

The company conducts its business operations out of leased properties, as it does not own any land or property. The text details several leased premises, including registered office and corporate offices, along with the terms and duration of the leases. Furthermore, the section outlines various Indian laws and regulations pertinent to the industry, such as the Drugs and Cosmetics Act, the Drugs Bill, the Cosmetic Rules, the NDPS Act, and various tax laws like the GST Act. These regulations govern the import, manufacture, distribution, and sale of various products and mandate specific record-keeping and licensing procedures.

This section details various Indian laws and regulations that govern different aspects of business operations, including foreign trade, foreign investment, environmental protection, labor relations, property transfer, intellectual property, and contract law. It outlines the framework provided by various acts and rules from central and state governments. Furthermore, it specifies that the company must comply with numerous other laws and regulations for its day-to-day operations, including those related to municipal laws, fire safety, and various tax laws. Setting up manufacturing units requires obtaining planning approvals from local authorities and various consents from state bodies.

The company was originally incorporated on August 2, 2004, as a private limited company. It later converted to a public limited company and changed its name to 'Goldline Pharmaceutical Limited' on July 18, 2013, resulting in a fresh certificate of incorporation in September 2013. The registered office has undergone several changes between its incorporation and the date of this prospectus. The Memorandum of Association has seen significant amendments regarding the authorized capital multiple times, including changes in the number of equity and preference shares. The company currently has no holding companies or subsidiaries as of the date of the prospectus.

This section details the directorship and association of various individuals with the company. It lists the details of Independent Directors, including their names, DINs, dates of birth, designations, and terms of directorship. It also mentions that certain Independent Directors serve on the board of a BSE-listed entity currently under suspension for non-compliance issues. The text further outlines various compliance confirmations regarding the directors, such as their status regarding defaulters, involvement with other companies, and lack of conflicts of interest with suppliers. It also specifies the board's authority to borrow money and details the terms for the appointment and remuneration of the Managing Director and Whole-time Director.

The company's corporate governance structure includes various committees established under the Companies Act and SEBI Listing Regulations. The Audit Committee was constituted on November 30, 2024, and the Nomination and Remuneration Committee was also formed on the same date. The Stakeholders’ Relationship Committee was formed on November 30, 2024, to address shareholder grievances. The text details the scope and powers granted to these committees, including oversight of financial reporting, related party transactions, and investor service quality.

This section details the composition of the committee responsible for the IPO process, outlining various powers related to the issue, financial statements, and agreements with intermediaries. It also introduces the Key Managerial Personnel (KMP) and Senior Managerial Personnel (SMP) of the company, including their roles, tenure, and remuneration details. The text further clarifies the relationship between KMP/SMP and the directors, the nature of payments made to KMP/SMP, and confirms the absence of conflicts of interest with suppliers and third-party service providers.

This section provides definitions and abbreviations used within the Prospectus. It identifies the company as Goldline Pharmaceutical Limited and specifies various terms related to the company, such as its legal name, registered office, and corporate identity number. It also defines various roles, such as the Promoter Group, auditors, and key management personnel. Furthermore, it details terms related to the issuance process, including different types of investors, bid procedures, and the role of the Book Running Lead Manager.

This section details various terms and definitions relevant to the issuance process, including who qualifies as a bidder, the nature of the issue, and the parties involved. It defines terms such as Designated Intermediaries, various accounts, investor categories, and the structure of the issue itself. It also specifies details regarding the filing of the Draft Red Herring Prospectus and the public announcement process.

This section primarily details various legal and regulatory terms, financial metrics, and conventions used throughout the Draft Red Herring Prospectus (DRHP). It lists numerous acronyms related to SEBI regulations, various acts, financial terms like RoNW and EBITDA, and definitions for industry-related terms. Furthermore, it outlines conventions regarding the use of financial information, currency conversions, and the reliability of industry data sources.

This section details various risk factors associated with the company's operations, primarily revolving around reliance on third-party manufacturers and market dependencies. Key risks include the potential failure of contract manufacturers to meet quality, delivery, or capacity requirements, delays in filing with the Registrar of Companies (RoC), and issues with payment of statutory dues like GST. Furthermore, the company's commercial success is dependent on its ability to analyze new pharmaceutical products, its reliance on distributors for revenue, and the potential for issues with product quality, supply chain disruptions, and litigation arising from contract agreements.

The company operates under a policy requiring formal third-party manufacturing agreements before placing any purchase order, utilizing multiple approved manufacturers to avoid single-source supply. Quality control involves ensuring third-party manufacturers maintain robust quality systems, including comprehensive quality management systems, adequate infrastructure, and stability studies. Products are only dispatched upon receiving a Certificate of Analysis (CoA) from the manufacturer, and random quality testing is conducted by government-approved laboratories. Contractual frameworks mandate adherence to guidelines prescribed by CDSCO and State FDA, and the company provides approved brand artwork. The company currently does not hold import or export licenses, limiting sales to within India, and is subject to inspections by CDSCO and State FDA authorities.

The company has faced instances of errors in filings with the Registrar of Companies (RoC), including incorrect face value of equity shares and misdesignation of a director's role, which could lead to future regulatory scrutiny. Furthermore, there have been delays in payment of statutory dues, such as GST, resulting in late fees, and there is no guarantee that such issues will not recur. The company also faces risks related to its commercial success, which depends on market analysis, and its reliance on third-party contract manufacturers for products. Additionally, there are outstanding litigations involving the company, its directors, key managerial personnel, senior management, and group companies, which could negatively impact the business and financial condition.

The company has identified potential conflicts of interest due to its promoter group entities being engaged in similar businesses, including distribution. The company has entered into distributorship agreements with these entities, though they are not restricted from dealing in other products. Furthermore, there is a non-compete agreement in place, but the company cannot guarantee that conflicts of interest will not arise in the future, which could adversely affect business opportunities. The company also faces risks related to product sales volume or pricing declining, and its reliance on limited geographies and customers. The company has also faced negative cash flows in the past, and its ability to manage or expand its distribution network is subject to risks from third-party intermediaries.

The provided text details various risks and dependencies faced by the company across several operational and financial aspects. Risks include the inability to anticipate market trends, the potential for product development initiatives to fail, and the vulnerability to adverse regulatory actions regarding permits and approvals. Furthermore, the business relies heavily on the performance of the marketing team and distributors, the reliability of third-party transportation providers, and the creditworthiness of end-users. The company also faces risks related to insurance adequacy, potential issues with delayed payments to MSME creditors, and the inherent risks associated with working capital requirements and inventory management.

The provided text highlights several risks related to internal controls, funding, property leases, business strategy implementation, reliance on IT systems, regulatory changes, product liability, patent litigation, competition, profitability maintenance, and promoter interests. It details potential adverse effects on the company's business, financial condition, and results of operations due to various external and internal factors. Furthermore, it discusses issues concerning the control exerted by promoters and the potential for future capital raising to dilute shareholder stakes.

The section discusses various risks related to the company's operations, financing, and governance. It covers issues such as related party transactions, the lack of alternate financing arrangements, restrictive covenants in borrowing agreements, and the potential impact of indebtedness. Furthermore, it addresses risks concerning the loss of key management personnel, the vulnerability to counterfeit products, and the lack of independent verification of industry data. Finally, it details the regulatory aspects concerning the issue, including the lack of a monitoring agency for the issue size, the requirement for shareholder approval for utilization of net proceeds, and the uncertainty surrounding the listing and trading of the equity shares.

The section discusses various risks related to the equity shares, including market volatility, potential adverse effects from promoter sales, and operational risks stemming from the business environment and regulatory changes. It highlights that the trading price can fluctuate due to numerous factors, including market volatility, competitor performance, and macroeconomic shifts. Furthermore, the section addresses risks associated with the business operations themselves, such as the potential for business strategy implementation failures, conflicts of interest with promoter group entities, and exposure to adverse changes in laws and regulations. Finally, it details risks from external factors like political instability, natural calamities, and global conflicts that could impact the business and financial performance.

The prospectus details the structure of a public issue involving a total of 27,0 equity shares, with a portion reserved for the Market Maker and a net issue to the public. The issue was categorized into three segments: QIB, Non-Institutional, and Individual Investors, with specific allocations defined by the SEBI ICDR Regulations. The document also outlines rules regarding the allocation of securities and the permissible proportions for different investor categories.

The provided text details various financial and transactional summaries, including contingent liabilities and related party transactions, as per the Restated Consolidated Financial Information. It also provides extensive details regarding the company's incorporation, registered office, board of directors, key officers, and the intermediaries involved in the issue process. Specific information is given about the claims against the company, related party transactions with various entities, and the contact and registration details for the Book Running Lead Manager, Registrar to the Issue, Legal Advisor, Auditor, and various banks.

This section details various procedural and regulatory aspects related to the issuance process, including the roles of different intermediaries and the mechanics of the book-building process. It outlines which entities are designated to act as Syndicate Banks, Brokers, Registrars, and Collecting Depository Participants, referencing various SEBI circulars for applicability. The text also specifies rules regarding the use of the ASBA mechanism and the process for bid submission, including timelines and rules for bid revisions. Furthermore, it describes the allocation of securities to different investor categories based on the net issue structure.

The issue is 100% underwritten by Cumulative Capital Private Limited, with the underwriting obligations subject to certain conditions. The Market Making Agreement was entered into with Nirman Share Brokers Private Limited to ensure compulsory market making for a minimum of three years from the listing date. The market maker is required to provide 2-way quotes for 75% of the time, and there are specific rules regarding the depth of quotes and execution guarantees. Various provisions detail the market maker's responsibilities, potential punitive actions, and the applicable price band structures based on the issue size.

This section details the capital structure of the company, including the breakdown of authorized, issued, and paid-up share capital, as well as the history of changes to the authorized share capital. The text also outlines various provisions regarding the issuance of securities, such as the nature of the issue and the history of allotments for equity and preference shares. Furthermore, it confirms that the company has not issued equity shares through certain schemes and discloses information about the shareholding pattern and encumbrances.

The section details the shareholding pattern of the company as of the date of the Prospectus filing, showing a breakdown of shares held by different categories. It also provides information on the shareholding of key individuals and entities over various time periods. Furthermore, it clarifies that the company has not made any initial public offers of equity shares or convertible securities in the preceding two years and outlines the company's current intentions regarding future capital structure changes.

The company intends to raise funds through a fresh issue of 27,0 equity shares at a price of ₹ 43 per share. The net proceeds from this issue are intended to be utilized for two main purposes: repayment of outstanding borrowings and general corporate purposes. The details show that a significant portion of the net proceeds is earmarked for debt repayment, with the remainder allocated to general corporate activities. The utilization plan is based on management estimates, though it is subject to various external factors and potential revisions. The issue also involves estimated expenses related to underwriting and other fees.

This section details various aspects related to the issuance process and the basis for determining the issue price. It outlines the rules for calculating selling commissions and processing fees for different types of brokers and investors. Furthermore, it specifies the factors considered in consultation with the BRLM to establish the Issue Price, including qualitative factors such as the experience of the promoters and the nature of the business. Quantitative factors, such as various Earnings Per Share metrics and Return on Net Worth, are also presented for investor evaluation.

The provided text primarily details various financial performance indicators and ratios for the company, comparing them against its listed peers across different fiscal years. It defines several key metrics such as EBITDA Margin, Profit After Tax (PAT) Margin, Return on Equity (RoE), Debt to Equity Ratio, Interest Coverage Ratio, Return on Capital Employed (RoCE), Current Ratio, and Net Capital Turnover Ratio. The text also includes notes clarifying the calculation methods for these indicators and mentions that the financial information is sourced from the respective annual reports of the listed industry peers.

This section, found in Annexure-A, details the possible special tax benefits available to the Company and its Equity Shareholders under the Income Tax Act, 1961. The document clarifies that, except as specifically mentioned, there are no special tax benefits available to the company under various tax laws, including the Income Tax Act, Customs Tariff Act, and various GST Acts. Furthermore, there are no special tax benefits available to the shareholders under the same provisions. The notes emphasize that the statement is only a summary and not a complete analysis, and it does not cover tax consequences outside of India.

The section outlines various exclusions for outstanding litigation, including criminal proceedings, regulatory actions, tax matters, and claims against the Company, its Directors, Promoters, or Group Companies. It details a materiality policy for certain litigations, defining thresholds based on turnover, net worth, and profit/loss. Specific pending litigation was disclosed, including a civil writ petition filed by the Regional Provident Fund Commissioner challenging an order related to provident fund remittances. Furthermore, details on pending tax cases involving the Company and tax proceedings involving the Promoters and Directors were provided. The section also details criteria for considering dues to creditors as material.

The text states that except as disclosed in the Management’s Discussion and Analysis of Financial Condition and Results of Operations on page 238, there have been no material developments since the date of the last financial statements disclosed in the Prospectus. It further asserts that no circumstances have materially and adversely affected, or are likely to affect, the trading or profitability of the Company, the value of its assets, or its ability to pay its liabilities within the next 12 months.

The company has obtained various material consents, licenses, and approvals from government and various agencies to conduct its business activities. This includes approvals related to the issuance of securities, agreements with stock exchanges, and numerous registrations under various central and state laws. The section details approvals from the Stock Exchange, agreements with the Central Depository Services Limited (CDSL) and National Securities Depository Limited (NSDL), and various certificates issued by regulatory bodies like the Employees’ Provident Fund Organisation and the Employees’ State Insurance Corporation. Furthermore, the company has secured various tax-related registrations and business-related licenses, alongside a significant portfolio of registered trademarks.

The section details various aspects related to the company's regulatory status, including trademark applications, approvals, and compliance confirmations. It lists several trademark applications with their respective dates and statuses, noting that some have been accepted and advertised. The section also confirms that no licenses or approvals are currently pending, expired, or required but unapplied for. Furthermore, it outlines several compliance confirmations regarding the company's adherence to various regulations and the status of its directors and the company itself.

The section details various regulatory compliance aspects related to the issuance of securities, including requirements for the Book Running Lead Manager and underwriting commitments. It confirms that the issue has been 100% underwritten, and it outlines conditions regarding the number of proposed allottees. Furthermore, it discusses compliance with SEBI ICDR Regulations and clarifies the responsibilities of the Book Running Lead Manager concerning due diligence and the filing of the prospectus. The text also includes disclaimers from BSE and the company, and specifies jurisdiction for disputes.

The company has received written consent from Statutory Auditors to include their name in reports related to restated financial information and tax benefits included in the Prospectus, and this consent remains valid. The company has not made any rights issues in the five years preceding the prospectus date, and no commission or brokerage has been paid for subscribing to equity shares in the five years prior to the prospectus date. Furthermore, the company's group companies are not listed on any stock exchanges, nor does it have any subsidiaries or associates as of the prospectus date. The text details various mechanisms and liabilities related to investor grievances, including timelines for resolution and compensation for delays in unblocking funds or resolving grievances.

The section details various compliance confirmations, including the company's commitment to resolve investor complaints within 30 days. It confirms that no investor complaints or pending complaints are currently pending for resolution. Furthermore, it states that the company has not received any findings or observations from SEBI regarding regulatory compliance. The text outlines the legal framework governing the equity share issue, including adherence to various laws and regulations. It specifies the terms for dividend payment and the pricing structure for the equity shares being issued.

This section details various procedural timelines and conditions related to the issuance and bidding process, including specific time windows for bid submissions and revisions across different types of bids. It also outlines requirements for compliance with listing timelines and the responsibility of the Book Running Lead Manager (BRLM) to report on adherence or non-adherence to these timelines. Furthermore, the text specifies various criteria for migration to the main board of the BSE, including requirements related to paid-up capital, market capitalization, market liquidity, operating profit, net worth, and promoter holding. It also lists several regulatory requirements concerning the company's track record and financial standing.

The shares proposed for issuance were to be listed on the SME Platform of BSE Limited with compulsory market making for a minimum of three years. The issue was conducted under Regulation 229 (2) of Chapter IX of SEBI ICDR Regulation, 2018, for an issuer with post-issue paid-up capital between ₹10 crores and ₹25 crores. The issue comprised a reservation for a Market Maker, a Net Issue to the public, and detailed provisions regarding the Book Building Process for various investor categories. Specific rules were laid out for allocation, including provisions for different application sizes and the allocation of portions to different investor types.

This section details various procedural aspects related to the bidding and allotment process for public issues, including rules regarding bid submission, investor eligibility, and the implementation of different payment mechanisms like UPI. It outlines rules concerning bid collation, the allocation of securities to different investor categories (Individual, Non-Institutional, QIBs), and various regulations from SEBI that govern the issuance of securities. It also discusses timelines and procedures for processing applications, including issues related to the blocking of funds and the transition to the UPI mechanism for faster listing.

This section details various regulatory timelines and procedures related to public issue listings, specifically concerning the transition to and implementation of the UPI mechanism. It outlines changes in the time duration between issue closure and listing, including the introduction of a T+3 phase. Furthermore, it specifies requirements for investor grievance redressal under the UPI mechanism, including the appointment of nodal officers and the handling of blocked funds. It also describes the process for processing payment fees and the role of Sponsor Banks in facilitating fund collection through UPI mandates.

This section details various categories of investors eligible to participate in the equity share issue, including Indian nationals, HUFs, various corporate bodies, mutual funds, FPIs, and insurance companies. It also outlines restrictions on who can submit applications, such as minors or foreign nationals, and clarifies rules regarding participation by promoters and their associates. Furthermore, the text specifies minimum application sizes for individual investors and details the process for bidding, including the timing and method of bid submission.

This section details various requirements and restrictions concerning different categories of bidders when applying for the issue, including rules for Hindu Undivided Families (HUFs), Mutual Funds, Eligible Non-Resident Indians (NRIs), Foreign Portfolio Investors (FPIs), and various financial institutions. Specific requirements include providing PAN details, certified copies of registrations, adherence to investment limits set by SEBI and RBI regulations, and procedures for handling funds, especially for NRIs and FPIs. There are also specific rules regarding the use of various bidding channels and the handling of multiple bids from certain entities.

This section details the procedures and terms related to bids for the issue, including provisions for Anchor Investors and Qualified Institutional Buyers (QIBs). It outlines various rules regarding bid amounts, allocation limits, and the process for finalizing allocations. Furthermore, it specifies requirements for bids made through power of attorney or by certain corporate bodies, and the use of the Application Supported by Blocked Amount (ASBA) process. The section also covers the handling of confirmations, payment mechanisms, and the electronic registration of applications.

This section details various procedural requirements and instructions for investors participating in the book-building and price discovery process. It outlines rules regarding bid submission, including eligibility checks, linking of PAN with Aadhaar, and adherence to various regulations. Specific instructions cover how bids must be submitted through the ASBA process, requirements for funds availability, and rules concerning the use of different payment mechanisms like UPI. It also specifies conditions for bid revision, submission of documents, and restrictions on the amount and type of bids.

This section details various procedural requirements and conditions related to the submission and processing of bids and applications for equity shares. It outlines several criteria that can lead to bid rejection, such as mismatches in PAN details, bids lacking required signatures, or bids from ineligible persons. Furthermore, the text discusses procedures for handling delays in fund unblocking and the basis for allotment, including proportionate allocation, oversubscription handling, and specific rules for different investor categories like Individual Investors, Non-Institutional Bidders, and QIBs.

The section details various procedural aspects related to the allotment process, including rules for rounding off shares to multiples of 3000, adjustments for shares between categories, and the responsibilities of the Designated Stock Exchange in ensuring a fair allotment basis according to SEBI (ICDR) Regulations. It outlines the process for issuing allotment advice, the timeline for credit of shares to successful bidders' accounts, and the requirements for submitting bid cum application forms. Furthermore, it specifies various undertakings by the company regarding the timely completion of formalities for listing and trading, as well as provisions concerning the disposal of application money and interest in case of delays.

The company is required to comply with the SEBI Listing Regulations, 2015 concerning the disclosure and monitoring of issue proceeds, and must await approval for listing and trading before accessing issue proceeds. The Book Running Lead Manager is obligated to address any complaints or comments related to the issue promptly. Regarding foreign investment, the text details various regulations under the Industrial Policy, 1991, and FEMA, including rules that mandate prior government approval for certain investments, such as those involving entities from land-bordering countries. FDI in the wholesale trading sector is permitted up to 100% under the automatic route, but certain entities are barred from participating. Furthermore, the company's Articles of Association detail provisions for share transfer, lien rights, and the process for issuing and dealing with share certificates.

This section details various procedural regulations concerning the transfer of shares, forfeiture of shares, alteration of capital, and general meeting proceedings. It outlines rules for handling the death or insolvency of a member, the process for electing to register or transfer shares, and the consequences of non-payment of calls on shares, which can lead to forfeiture. Furthermore, the text covers provisions related to the increase or reduction of share capital, the capitalization of profits, and the power of the company to purchase its own securities. It also specifies rules for conducting general meetings, including quorum requirements, the role of the chairperson, and voting rights.

This section primarily details various contractual agreements and documents that may be considered material for inspection, which were delivered to the Registrar of Companies (ROC) for the Red Herring Prospectus filing. It lists numerous material contracts related to the issue, as well as various corporate documents, resolutions, examination reports, and consents from numerous parties. The section also includes several certificates and agreements related to compliance with the Companies Act provisions concerning past allotments, reconciliation of equity, borrowings, and industry reports.

The provided section primarily consists of multiple declarations certifying compliance with various provisions of the Companies Act and regulations issued by the Government of India or SEBI. These declarations are signed by different directors, confirming that the statements made in the Prospectus are true and correct. No specific regulatory approvals, licenses, non-compliance issues, or pending applications are detailed in this excerpt.

The provided section consists entirely of declarations certifying compliance with various laws and regulations. The declarations confirm that all relevant provisions of the Companies Act and guidelines issued by the Government of India or SEBI have been complied with. Furthermore, the declarations assert that no statement in the Prospectus contradicts the provisions of the Companies Act, SCRA, SCRR, SEBI Act, or related rules and guidelines. The declarations are signed by a Director and a Chief Financial Officer, respectively, affirming the truth and correctness of the disclosures.

This section details the history of shareholding build-up and transfers involving the company's promoters and various transactions with other parties. It outlines numerous allotments, transfers, and bonus issues, specifying the consideration, number of shares, and percentage changes. Furthermore, it establishes conditions regarding the lock-in of a minimum promoter's contribution under SEBI (ICDR) Regulations, including timelines and restrictions on the disposal or transfer of these shares.

The management section details various compliance and procedural aspects related to the issuance of equity shares. It confirms that there will be no further equity share issues during a specified period and that the company has no outstanding warrants, options, or rights to convert instruments into equity shares. Furthermore, it outlines rules regarding transactions by promoters and the promoter group, the nature of equity share allotment, and restrictions on investors and financial arrangements.

The company's promoters are Amol Laxmikant Mujumdar and Swapan Premprakash Khandelwal, who collectively hold 79.70% of the equity shares. The details provided include their personal information and shareholding percentages. The document confirms that there has been no change in management or control over the last five years. Furthermore, the document details the interests of the promoters, including transactions with other entities and confirms that the promoters have not extended personal guarantees or advanced unsecured loans for the company's bank loans. The document also lists various entities that form part of the Promoter Group and confirms that the promoters and their group have not been declared wilful defaulters or prohibited from accessing capital markets by SEBI.

The company identified several group companies based on related party transactions, including Cherry Voyaging Private Limited, Activista Healthcare Private Limited, Nucleage Pharma Solutions Private Limited, and Numerius Healthcare Private Limited. Details regarding the registered offices and financial performance data for these entities are available on the company's website. The company confirmed that its group companies are not involved in litigation, similar business activities, or transactions concerning the acquisition of land, construction, or machinery with the company. Furthermore, the group companies do not hold equity shares or warrants in the company, nor are they listed entities or recent public/rights issue issuers.

This section details the process of compiling and re-auditing the company's financial statements for various periods. The Restated Financial Statements were compiled by the management based on audits conducted by different firms, including M/s Shah & Raut Chartered Accountants for certain years. The auditors' reports for specific periods showed no material audit qualifications requiring adjustments to the Restated Financial Statements. Furthermore, the work was performed to ensure compliance with the Act, ICDR Regulations, and relevant Guidance Notes.

The provided text details various financial statements and disclosures, including cash flow, profit/loss reconciliations, share capital structure, and details of loans and deferred tax liabilities. It shows financial performance metrics across different fiscal years, reconciliations for profit and revenue, and information regarding the ownership structure of the company. Furthermore, the document lists numerous long-term borrowings from various financial institutions and details the terms and conditions for repayment of these loans.

The provided section details various financial statements and notes related to Goldline Pharmaceutical Limited, including long-term liabilities, short-term borrowings, trade payables, current liabilities, provisions, assets, receivables, cash, loans, and revenue from operations. It also includes disclosures regarding related parties, such as Key Management Personnel (KMP) and Directors, and various financial ratios. Specific details on the structure of the company's liabilities, assets, and operational performance are presented across these appendices.

The provided text details various financial relationships, remuneration, and transactions within Goldline Pharmaceutical Limited, including relationships with several other entities. It lists directors, partners, and a CFO, along with details on remuneration and various balances such as trade receivables and payables. Furthermore, the text includes financial statements showing trends in profit, assets, liabilities, and various financial ratios over different periods. It also contains disclosures regarding debt, shareholder funds, and compliance with certain regulations.

The provided text primarily contains financial ratios and performance metrics for a company, including profit, earnings, inventory turnover, trade receivables turnover, capital turnover, net profit margins, and interest coverage. It details various financial statements and accounting policies, such as the basis of preparation, use of estimates, depreciation methods, and revenue recognition. The text also mentions the company's history, including its conversion from a private to a public limited company and the nature of its business in marketing pharmaceutical products. The text outlines accounting standards used and the treatment of various items like contingent liabilities and employee benefits.

This section primarily contains details regarding the financial workings and ratios of Goldline Pharmaceutical Limited, including various accounting ratios derived from restated financial statements. It provides data for nine-month periods ending December 31, 2025, and annual periods ending March 31, 2025, 2024, and 2023. The data includes metrics such as Total Revenue, Net Profit, EBITDA, Net Worth, and various earnings per share calculations. The text also clarifies that the audited financial statements are available on the company's website but should not be relied upon as part of the Red Herring Prospectus.

This section details the financial indebtedness of the company, outlining various loans obtained for business requirements. The text lists several facilities, including secured and unsecured loans from various financial institutions, specifying the amounts, outstanding balances as of March 31, 2026, interest rates, and tenure. A significant portion of the loans involves personal guarantees and co-borrowers, including Amol Laxmikant Mujumdar and Swapan Premprakash Khandelwal, for certain facilities. The section also details various restrictive covenants and events of default that lenders may invoke.

The company is engaged in marketing pharmaceutical products under the brand name “Goldline,” utilizing contractual arrangements with third-party manufacturers for production. The company maintains contractual arrangements with 15 manufacturers and 8 distributors to ensure a stable supply chain. The analysis of financial performance shows that while revenue has increased consistently, profitability has been constrained by high operating costs, including increased overheads, selling and distribution expenses, and finance costs. Furthermore, the margin expansion achieved in FY 2025 was moderated by a significant increase in depreciation expense due to new fixed asset additions.

The provided text details various financial performance highlights and cash flow movements for the company across fiscal years. Revenue from operations showed an increase from FY 2024 to FY 2025, with the company recording revenue from operations of ₹ 2,140.63 lakhs during the period ended December 31, 2025. Profit after tax (PAT) reflected stable profitability, with PAT margin increasing from 7.66% in FY 2024 to 10.10% in FY 2025. Cash flow analysis shows net cash generated from operating activities, investing activities, and financing activities across the three fiscal years, with various cash movements related to borrowings, dividends, and asset purchases.

This section details operational aspects of the company, including how changes in net sales or revenue are related to sales volume, new product introductions, or price changes. The company asserts that revenue increases are primarily linked to business volume, and it states that the business is not seasonal. Furthermore, the text provides detailed breakdowns of the company's dependence on suppliers and customers, showing the percentage contribution of top suppliers and customers to total purchases and revenues, respectively. The section also directs readers to other chapters for industry data and competitive conditions.